6-Chloro-3-ethyl-2-methylimidazo[1,2-b]pyridazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-Chloro-3-ethyl-2-methylimidazo[1,2-b]pyridazine
• 英文别名: 6-chloro-3-ethyl-2-methylimidazo[1,2-b]pyridazine
• 化学式: C₉H₁₀ClN₃
• 分子量: 195.65
• InChiKey: FTGMRCZRVBZQRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline, LLC

  公开号：US20140349993A1

  公开（公告）日：2014-11-27

  Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新颖的取代双环氮杂杂环丝氨酸调节化合物及其使用方法。这些丝氨酸调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或压力有关的疾病或疾病、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或疾病。还提供了包含丝氨酸调节化合物与另一种治疗剂组合的组合物。
• 4-phenylpiperidines, their preparation and use
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US10273243B2

  公开（公告）日：2019-04-30

  The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有以下结构的化合物：(结构表示），其中 R1、R2、R3、R4 和 R5 各自独立地为 H、卤素、CF3 或 C1-C4 烷基；R6 为 H、OH 或卤素；B 为取代或未取代的杂环、哒嗪、吡唑、吡嗪、噻二唑或三唑，其中杂环为氯取代的吲哚以外的杂环；吡唑取代时为三氟甲基以外的取代基，或其药学上可接受的盐。
• CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
  申请人：Ionis Pharmaceuticals, Inc.

  公开号：US20170355727A1

  公开（公告）日：2017-12-14

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine analogues.
• US9957271B2
  申请人：——

  公开号：US9957271B2

  公开（公告）日：2018-05-01